Drug intelligence / Profile preview

Mozenavir

Development stage: Preclinical
Lead developer: DuPont
Modality: Small Molecules
Administration: Oral

Overview

Mozenavir is a small molecule, non-peptidic HIV-1 protease inhibitor. It functions by blocking the protease enzyme, which is crucial for the maturation of new HIV viral particles. This mechanism prevents the virus from assembling into its mature, infectious form. Mozenavir was also investigated through *in silico* studies as a potential antiviral agent against SARS-CoV-2, demonstrating strong binding affinity to several viral targets, particularly furin, suggesting it could inhibit its proteolytic activity.

Targets

ACE2 (Angiotensin-converting enzyme 2)PR (Progesterone receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)SARS-CoV-2 spikeFurinMpro (3C-like proteinase of SARS-CoV-2)TMPRSS2 (Transmembrane protease serine 2)

Beyond the preview

Go deeper on Mozenavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mozenavir.

Explore the full profile